Physician profile
John V Anooshian
NPI 1235189705
$835,567.33
in general payments reported to CMS, 2019-2025
21 companies · $154K in 2025
The $154K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $32K · 2021: $67K · 2022: $188K · 2023: $130K · 2024: $202K · 2025: $154K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $352K · Travel and Lodging: $78K · Consulting Fee: $32K · Food and Beverage: $24K · Education: $20.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $351,537.00 |
| Travel and Lodging | $77,905.24 |
| Consulting Fee | $32,118.00 |
| Food and Beverage | $23,616.85 |
| Education | $20.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $345,402.37 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Neurocrine Biosciences, INC. | $343,560.60 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87,062.23 | 2020-2025 | Caplyta |
| Abbvie INC. | $28,353.84 | 2021-2025 | Vraylar |
| Alkermes, INC. | $10,569.98 | 2019-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $7,907.32 | 2024-2025 | Cobenfy |
| Allergan, INC. | $5,362.81 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $3,720.55 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,545.65 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $815.62 | 2019-2025 | Uzedy |
| Indivior INC. | $239.67 | 2022-2024 | Perseris |
| Lundbeck LLC | $220.45 | 2019-2023 | Rexulti |
| Janssen Scientific Affairs, LLC | $190.92 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Avadel Cns Pharmaceuticals, LLC | $150.00 | 2025 | Lumryz |
| Tris Pharma INC | $149.08 | 2019-2024 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $125.99 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $122.82 | 2019-2024 | Fanapt |
| Eisai INC. | $18.99 | 2021 | |
| Sumitomo Pharma America, INC. | $17.22 | 2023 | Latuda |
| Takeda Pharmaceuticals U.S.A., INC. | $16.61 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.61 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Anooshian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.